Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration
Open Access
- 14 April 2023
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (8) , 2870
Abstract
The complement system is crucial for immune surveillance, providing the body’s first line of defence against pathogens. However, an imbalance in its regulators can lead to inappropriate overactivation, resulting in diseases such as age-related macular degeneration (AMD), a leading cause of irreversible blindness globally affecting around 200 million people. Complement activation in AMD is believed to begin in the choriocapillaris, but it also plays a critical role in the subretinal and retinal pigment epithelium (RPE) spaces. Bruch’s membrane (BrM) acts as a barrier between the retina/RPE and choroid, hindering complement protein diffusion. This impediment increases with age and AMD, leading to compartmentalisation of complement activation. In this review, we comprehensively examine the structure and function of BrM, including its age-related changes visible through in vivo imaging, and the consequences of complement dysfunction on AMD pathogenesis. We also explore the potential and limitations of various delivery routes (systemic, intravitreal, subretinal, and suprachoroidal) for safe and effective delivery of conventional and gene therapy-based complement inhibitors to treat AMD. Further research is needed to understand the diffusion of complement proteins across BrM and optimise therapeutic delivery to the retina.Keywords
Funding Information
- Newcastle University (ACF-2021-01-008, #GR602, #GR601)
- Gyroscope Therapeutics, a Novartis company (ACF-2021-01-008, #GR602, #GR601)
- NIHR Academic Clinical Fellowship (ACF-2021-01-008, #GR602, #GR601)
- Retina UK (ACF-2021-01-008, #GR602, #GR601)
- Macular Society UK (ACF-2021-01-008, #GR602, #GR601)
- companies developing complement therapeutics (ACF-2021-01-008, #GR602, #GR601)
- Gyroscope Therapeutics (a Novartis company) (relevant to work under consideration), Alcon, Boehringer Ingelheim, Bayer, DORC, and Roche (ACF-2021-01-008, #GR602, #GR601)
This publication has 310 references indexed in Scilit:
- Properdin and Factor H: Opposing Players on the Alternative Complement Pathway “See-Saw”Frontiers in Immunology, 2013
- Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 MutationsArchives of Ophthalmology (1950), 2012
- Functional modulation of human monocytes derived DCs by anaphylatoxins C3a and C5aImmunobiology, 2012
- Elevated membrane attack complex in human choroid with high risk complement factor H genotypesExperimental Eye Research, 2011
- Retinal pigment epithelial expression of complement regulator CD46 is altered early in the course of geographic atrophyExperimental Eye Research, 2011
- The alternative pathway is required, but not alone sufficient, for retinal pathology in mouse laser-induced choroidal neovascularizationMolecular Immunology, 2011
- Suprachoroidal Drug Delivery to the Back of the Eye Using Hollow MicroneedlesPharmaceutical Research, 2010
- Locally Produced Complement Fragments C5a and C3a Provide Both Costimulatory and Survival Signals to Naive CD4+ T CellsImmunity, 2008
- Age-related changes in human macular Bruch's membrane as seen by quick-freeze/deep-etchExperimental Eye Research, 2007
- Fibulin-5 distribution in human eyes: Relevance to age-related macular degenerationExperimental Eye Research, 2007